Lonza Bend (US) upgrades capabilities in early phase clinical manufacturing services with the addition of bottling and labeling equipment
The inspections concluded with no Form 483 observations or significant critical findings
_256_384.jpg)
€ 6.6 million investment at Nantong site expands production capabilities for cell culture media
The facility was inspected from May 7 to May 17, 2024
The USFDA has issued 15 observations pursuant to the completion of audit. JHSGP will submit an action plan on the observations
New software solution helps manufacturers digitalize and gain insights from data to increase efficiency
DurA Cycle is designed for large-scale commercial manufacturing of monoclonal antibodies,
Largest investment in active pharmaceutical ingredient manufacturing of synthetic medicines in U.S. history
Operationally ready by 2029, it will be the Company’s first-ever facility to cover the full manufacturing process for ADCs
The USFDA has issued 5 observations pursuant to the completion of audit
Subscribe To Our Newsletter & Stay Updated
